AIMClinical Trials•globenewswire•
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Sentiment:Negative (30)
Summary
Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 21, 2025 by globenewswire